BaseSpace
Correlation
Engine-Public
Sign In
Register
Correlation Engine 2.0
Home
My Data
Bookmarks
Collaborations
Inbox
Import Your Data
QuickView
FAQ
What is QuickView?
What can my QuickView results tell me?
What are the sources for the General Info tab in QuickView?
More QuickView FAQs
Back to top
QuickView
Curated
Studies
Body
Atlas
Disease
Atlas
Pharmaco
Atlas
Knockdown
Atlas
Genetic
Markers
Pathway
Enrichment
Literature
Clinical
Trials
0
Meta-
Analysis
QuickView
Search sequence regions
(e.g.
rs2476601
,
LEP
,
G-protein-coupled receptor binding
,
Inflammatory disorder
,
Pancreas
)
Organisms
Chromosomes
Start
Stop
Homo Sapiens
Mus Musculus
Rattus Norvegicus
C. Elegans
D. Melanogaster
Saccharomyces Cerevisiae
QuickView
Go back to main search
Bookmark
Forward
QuickView
for
class i phosphatidylinositol 3- kinase
Summary
General Info
Curated Studies
Most Correlated Studies
Human breast cancer cell (T47D) gene expression after treatment with GDC-0941
Explore Curated Studies Results
Literature
Most Relevant Literature
Somatic non-cancerous overgrowth syndrome of obscure molecular etiology: what are the causes and opt…
Intermittent PI3Kδ Inhibition Mitigates Immune-Related Adverse Events.
The biomarker PIK3CA in tumor pathology].
Histopathologic Grading Is of Prognostic Significance in Primary Angiosarcoma of Breast: Proposal of…
Complex vascular anomalies and tissue overgrowth of limbs associated with increased skin temperature…
Explore Literature Results
Clinical Trials
Most Relevant Clinical Trials
Phase 1 Study of PI3 (Phosphatidylinositol-3)-Kinase Inhibitor Copanlisib With Gemcitabine or Cispla…
Phase I Study of PI3(Phosphoinositol 3)-Kinase Inhibitor BAY80-6946 With Paclitaxel in Patients With…
Pharmacodynamic Study of BKM120 in Breast Cancer
Phase I Study of Combination of Gedatolisib With Palbociclib and Faslodex in Patients With ER+/HER2-…
A Multicenter Phase I/II Trial of Abiraterone Acetate + BEZ235 in Metastatic, Castration-Resistant P…
Explore Clinical Trials Results
search
→
result
search
→
result
See more about this page
See complete FAQ